Prevalence and prognosis of malignancy in THSD7A-associated membranous nephropathy: a systematic literature review and clinical case study

References

• Wu YQ, Wang Z, Xu HF, et al. Frequency of primary glomerular disease in northeastern China. Braz J Med Biol Res. 2011;44(8):1–11. doi: 10.1590/S0100-879X2011007500089.
   PubMed Web of Science ®Google Scholar
• Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004;66(3):920–923.
   PubMed Web of Science ®Google Scholar
• Beck LH, Salant DJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int. 2010;77(9):765–770. doi: 10.1038/ki.2010.34.
   PubMed Web of Science ®Google Scholar
• Beck LHJr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21. doi: 10.1056/NEJMoa0810457.
   PubMed Web of Science ®Google Scholar
• Tomas NM, Beck LHJr., Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–2287. doi: 10.1056/NEJMoa1409354.
   PubMed Web of Science ®Google Scholar
• Iwakura T, Ohashi N, Kato A, et al. Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy. PLOS One. 2015;10(9):e0138841. doi: 10.1371/journal.pone.0138841.
   PubMed Web of Science ®Google Scholar
• Larsen CP, Cossey LN, Beck LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol. 2016;29(4):421–426. doi: 10.1038/modpathol.2016.32.
   PubMed Web of Science ®Google Scholar
• Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail. 2018;40(1):306–313.
   PubMed Web of Science ®Google Scholar
• Hoxha E, Beck LHJr., Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28(2):520–531. doi: 10.1681/ASN.2016010050.
   PubMed Web of Science ®Google Scholar
• Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642–1651.
   PubMed Web of Science ®Google Scholar
• Stevens LA, Claybon MA, Schmid CH, et al. Evaluation of the chronic kidney disease epidemiology collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int. 2011;79(5):555–562. doi: 10.1038/ki.2010.462.
   PubMed Web of Science ®Google Scholar
• Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int. 2021;99(4):967–976. doi: 10.1016/j.kint.2020.07.039.
   PubMed Web of Science ®Google Scholar
• von Haxthausen F, Reinhard L, Pinnschmidt HO, et al. Antigen-specific IgG subclasses in primary and malignancy-associated membranous nephropathy. Front Immunol. 2018;9:3035. doi: 10.3389/fimmu.2018.03035.
   PubMed Web of Science ®Google Scholar
• Hara S, Tsuji T, Fukasawa Y, et al. Clinicopathological characteristics of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy. Virchows Arch. 2019;474(6):735–743. doi: 10.1007/s00428-019-02558-0.
   PubMed Web of Science ®Google Scholar
• Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616–622. doi: 10.1038/modpathol.2017.163.
   PubMed Web of Science ®Google Scholar
• Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int. 2019;95(3):666–679. doi: 10.1016/j.kint.2018.10.024.
   PubMed Web of Science ®Google Scholar
• Hanset N, Aydin S, Demoulin N, et al. Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study. Am J Kidney Dis. 2020;76(5):624–635. doi: 10.1053/j.ajkd.2020.04.013.
   PubMed Web of Science ®Google Scholar
• Jianing L. Diagnostic study of serum anti-M type phospholipase A2 receptor (PLA2R) antibody negative idiopathic membranous nephropathy [dissertation]. Peking Union Medical College; 2015.
   Google Scholar
• De Vriese AS, Glassock RJ, Nath KA, et al. A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421–430. doi: 10.1681/ASN.2016070776.
   PubMed Web of Science ®Google Scholar
• Kuo MW, Wang CH, Wu HC, et al. Soluble THSD7A is an N-glycoprotein that promotes endothelial cell migration and tube formation in angiogenesis. PLOS One. 2011;6(12):e29000. doi: 10.1371/journal.pone.0029000.
   PubMed Web of Science ®Google Scholar
• Hoxha E, Wiech T, Stahl PR, et al. A mechanism for cancer associated membranous nephropathy. N Engl J Med. 2016;374(20):1995–1996. doi: 10.1056/NEJMc1511702.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Chen D, et al. Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy. J Clin Pathol. 2019;72(10):705–711. doi: 10.1136/jclinpath-2019-205852.
   PubMed Web of Science ®Google Scholar
• Stahl PR, Hoxha E, Wiech T, et al. THSD7A expression in human cancer. Genes Chromosomes Cancer. 2017;56(4):314–327. doi: 10.1002/gcc.22440.
   PubMed Web of Science ®Google Scholar
• Timmermans SA, Ayalon R, van Paassen P, et al. Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Am J Kidney Dis. 2013;62(6):1223–1225. doi: 10.1053/j.ajkd.2013.07.019.
   PubMed Web of Science ®Google Scholar
• Augert A, Payré C, de Launoit Y, et al. The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep. 2009;10(3):271–277. doi: 10.1038/embor.2008.255.
   PubMed Web of Science ®Google Scholar
• Bernard D, Vindrieux D. PLA2R1: expression and function in cancer. Biochim Biophys Acta. 2014;1846(1):40–44. doi: 10.1016/j.bbcan.2014.03.003.
   PubMed Web of Science ®Google Scholar
• Lin F, Zhang D, Chang J, et al. THSD7A-associated membranous nephropathy in a patient with neurofibromatosis type 1. Eur J Med Genet. 2018;61(2):84–88.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Gong T, Rennke HG, et al. Duodenal schwannoma as a rare association with membranous nephropathy: a case report. Am J Kidney Dis. 2019;73(2):278–280.
   PubMed Web of Science ®Google Scholar
• Wang CH, Chen IH, Kuo MW, et al. Zebrafish THSD7A is a neural protein required for angiogenic patterning during development. Dev Dyn. 2011;240(6):1412–1421.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–257. doi: 10.1038/35025220.
   PubMed Web of Science ®Google Scholar
• Leeaphorn N, Kue-A-Pai P, Thamcharoen N, et al. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol. 2014;40(1):29–35. doi: 10.1159/000364782.
   PubMed Web of Science ®Google Scholar
• Xian L, Dong D, Luo J, et al. Expression of THSD7A in neoplasm tissues and its relationship with proteinuria. BMC Nephrol. 2019;20(1):332. doi: 10.1186/s12882-019-1489-5.
   PubMed Web of Science ®Google Scholar